Skip to content
A Green Sign – Lifestyle
Author:
MapLight Therapeutics, Inc.
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
BANKFIRST CAPITAL CORPORATION Reports First Quarter 2026 Earnings of $8.39 Million
April 29, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
1
2
Next Page
→